Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophy
(WorldNews Switzerland)

Santhera Pharmaceuticals Holding AG Hohenrainstrasse 24, 4133 Pratteln, Switzerland Phone: +41 61 906 89 50 | Fax: +41 61 906 89 51 www.santhera.com Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophy Pratteln, Switzerland, November 19, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces publication of the previously reported SYROS study data in prominent peer-reviewed medical journal Neuromuscular Disorders[1], demonstrating long-term efficacy with idebenone in slowing respiratory function loss in patients with Duchenne muscular dystrophy (DMD) under routine clinical care. The publication reports data collected as retrospective cohort...